Replies to post #10043 on Inovio Pharmaceuticals Inc (INO)

[jevansac]

I've been looking for a trustworthy valuation and would really like to understand the process on how Roche valued INO. Can you point me to where you got this information, I re-read the 8-K this morn but it's not there as far as I can tell.
Are you saying they valued the company at 400 million+ because of the $412.5 million in milestones payments?

[ImaPseudonym]

Roche didn't value INO at 400 mil. They offered that amount in milestones for about 1/4 of the *current* pipeline (and not even the furthest along). There isn't any chance INO directors would accept the offer, but do you really think that Roche wouldn't have offered 500 mil. to buy the entire company/ip portfolio outright? Or 600 mil.? Etc. We have no idea what value Roche places on the entire company right now.

[Everywhereman]

Roche valued ONE pre clinical (animal studies) vaccine at 400 million Not Inovio. If that is worth 400 million it is easy to say that the HPV/cancer vaccine nearing the end of phase 2 is worth at least 2 times as much. Then you would value all of the Phase 1 trial vaccines at at least 50% more... You can easily compute a value at over 2 billion for the company based on that alone. That does not include the many other pre clinical drugs.....